

Covidien plc  
Form 8-K  
July 29, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 29, 2009**

**COVIDIEN PUBLIC LIMITED COMPANY**

(Exact Name of Registrant as Specified in Charter)

**Ireland**  
(State or Other Jurisdiction

of Incorporation)

**001-33259**  
(Commission File Number)

**98-0624794**  
(I.R.S. Employer Identification No.)

**Cherrywood Business Park**

**Block G, First Floor**

Edgar Filing: Covidien plc - Form 8-K

**Loughlinstown, Co.**

**Dublin, Ireland**

**(Address of Principal Executive Offices, including Zip Code)**

**+353 (1) 439-3000**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On July 29, 2009, Covidien plc (the Company) issued a press release announcing entry into a definitive agreement to acquire Power Medical Interventions, Inc. (PMI), a provider of computer-assisted, power-actuated surgical cutting and stapling products.

The Board of Directors of both companies unanimously approved the transaction, pursuant to which an indirect, wholly-owned subsidiary of the Company will pay \$2.08 in cash per share of PMI common stock. Aggregate consideration, including assumption of debt, will total approximately \$64 million. The transaction, which will take the form of an all cash tender offer, is subject to customary closing conditions and is expected to be completed by September 25, 2009.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

***Important Additional Information Will Be Filed with the Securities and Exchange Commission (SEC)***

This current report is neither an offer to purchase nor a solicitation of an offer to sell shares of PMI. Covidien Delaware Corp. (the Merger Sub), an indirect, wholly-owned subsidiary of the Company, has not commenced the tender offer for the shares of PMI stock described in this current report.

Upon commencement of the tender offer, the Merger Sub will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Following commencement of the tender offer, PMI will file with the SEC a tender offer solicitation/recommendation statement on Schedule 14D-9. These documents will contain important information about the Company, Merger Sub, PMI, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available.

Investors and security holders will be able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by the Merger Sub and PMI through the web site maintained by the SEC at [www.sec.gov](http://www.sec.gov). In addition, investors and security holders will be able to obtain free copies of these documents by contacting: Covidien, Investor Relations, 508-452-4650, [investor.relations@covidien.com](mailto:investor.relations@covidien.com).

**Item 9.01. Financial Statements and Exhibits**

(d) *Exhibits*

99.1 Press Release dated July 29, 2009

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COVIDIEN PLC

By: /s/ John W. Kapples  
John W. Kapples  
Vice President and Secretary

Date: July 29, 2009

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit Name</b>
<b>99.1</b>	<b>Press Release dated July 29, 2009</b>